VIEW on M&A
Big pharma is at a pivotal point in its evolution. A recent report by PricewaterhouseCoopers suggests a shortage of promising products in the pipeline underlies many of the challenges faced by the life-sciences sector, including its deteriorating financial performance, increased sales and marketing expenditures, and negative press. The business reality is that the industry is spending twice as much on R&D as it was 10 years ago to produce fewer than half the new medicines it produced then. The basic research upon which drug discovery relies is becoming prohibitively expensive as academic institutions increase the valuation of their research and competition for these assets intensifies. The current financial climate, political trends, and quantum shifts in the way healthcare is delivered and measured are further creating pressure on companies to…
Expert on this topic
Pat Golomb is VP of Business Development, M Squared Consulting, Life Sciences, a specialty practice area of M Squared Consulting Inc. that offers customized consulting solutions, as well as in-sourced flexible resources-on-demand to meet the project-based talent requirements of pharmaceutical, biotech, and medical-device companies. For more information, visit msquaredlifesciences.com.